Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Altimmune (Nasdaq: ALT) announced that their Chief Medical Officer, Dr. Scott Harris, will present at the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. The presentation will focus on body composition data from the Phase 2 MOMENTUM trial of pemvidutide in obesity treatment. Dr. Harris will participate in a panel discussion titled 'Muscle Wasting in Weight Loss Therapy' during the session 'Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues' on Friday, December 6, 2024, at 9:30 am ET.
Altimmune (Nasdaq: ALT) ha annunciato che il loro Chief Medical Officer, il Dr. Scott Harris, presenterà alla 17ª Conferenza Internazionale della Società sulla Sarcopenia, Cachexia e Disturbi da Perdita di Peso a Washington, D.C. La presentazione si concentrerà sui dati compositivi del corpo provenienti dalla fase 2 dello studio MOMENTUM sul pemvidutide nel trattamento dell'obesità. Il Dr. Harris parteciperà a una discussione di panel intitolata 'Perdita Muscolare nella Terapia per la Perdita di Peso' durante la sessione 'Approcci al Trattamento per Affrontare la Perdita Muscolare nel Contesto della Terapia per l'Obesità e Questioni Regolatorie' venerdì 6 dicembre 2024, alle 9:30 ET.
Altimmune (Nasdaq: ALT) anunció que su Director Médico, el Dr. Scott Harris, presentará en la 17ª Conferencia Internacional de la Sociedad sobre Sarcopenia, Caquexia y Trastornos de Pérdida de Peso en Washington, D.C. La presentación se centrará en datos de composición corporal del ensayo MOMENTUM de fase 2 sobre el pemvidutide en el tratamiento de la obesidad. El Dr. Harris participará en una discusión en panel titulada 'Pérdida Muscular en la Terapia de Pérdida de Peso' durante la sesión 'Enfoques de Tratamiento para Abordar la Pérdida Muscular en el Contexto de la Terapia de Obesidad y Cuestiones Regulatorias' el viernes 6 de diciembre de 2024, a las 9:30 am ET.
Altimmune (Nasdaq: ALT)는 그들의 최고 의료 책임자 Dr. Scott Harris가 워싱턴 D.C.에서 열리는 제17회 국제 사르코페니아, 악액질 및 체중 감소 장애 학회에서 발표할 것이라고 발표했습니다. 발표는 비만 치료를 위한 pemvidutide의 2상 MOMENTUM 시험에서의 신체 성분 데이터에 초점을 맞출 것입니다. Dr. Harris는 '비만 치료 및 규제 문제의 맥락에서 근육 손실 치료 접근법' 세션에서 '체중 감소 요법의 근육 손실'라는 제목의 패널 토론에 참여할 것입니다. 이 행사는 2024년 12월 6일 금요일 오전 9시 30분 ET에 진행됩니다.
Altimmune (Nasdaq: ALT) a annoncé que leur médecin-chef, Dr. Scott Harris, présentera à la 17e Conférence Internationale de la Société sur la Sarcopénie, la Cachexie et les Troubles de la Perte de Poids à Washington, D.C. La présentation sera axée sur les données de composition corporelle de l'essai MOMENTUM de phase 2 sur le pemvidutide dans le traitement de l'obésité. Dr. Harris participera à une table ronde intitulée 'Perte Musculaire dans la Thérapie de Perte de Poids' lors de la session 'Approches de Traitement pour Aborder la Perte Musculaire dans le Cadre de la Thérapie de l'Obésité et des Questions Réglementaires' le vendredi 6 décembre 2024 à 9h30 ET.
Altimmune (Nasdaq: ALT) gab bekannt, dass der Chief Medical Officer, Dr. Scott Harris, auf der 17. Internationalen Konferenz der Gesellschaft für Sarkopenie, Kachexie und Abbaukrankheiten in Washington, D.C. präsentieren wird. Die Präsentation wird sich auf Körperzusammensetzungsdaten aus der Phase-2-Studie MOMENTUM zu Pemvidutid bei der Behandlung von Adipositas konzentrieren. Dr. Harris wird an einer Podiumsdiskussion mit dem Titel 'Muskelabbau in der Gewichtsreduktionstherapie' während der Sitzung 'Behandlungsansätze zur Bekämpfung des Muskelabbaus im Kontext der Adipositas-Therapie und regulatorischen Fragen' am Freitag, den 6. Dezember 2024, um 9:30 Uhr ET teilnehmen.
- None.
- None.
GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.
Details for the panel discussion are as follows:
| Title: | Muscle Wasting in Weight Loss Therapy |
| Session: | Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues |
| Presenter: | Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc. |
| Date/Time: | Friday, December 6, 2024 at 9:30 am ET |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
What will Altimmune (ALT) present at the Cachexia Conference in December 2024?
When is Altimmune's (ALT) presentation at the Sarcopenia and Cachexia Conference 2024?
What clinical trial data will Altimmune (ALT) discuss at the December 2024 conference?
What is the topic of Altimmune's (ALT) panel discussion at the December 2024 conference?
